Patents by Inventor Myoung Suh
Myoung Suh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220298513Abstract: The present invention relates to a method of identifying an intracellular secretory protein or tissue-specific secretory protein, by using a proximity labeling system. When the method according to the present invention is used, it is possible to clearly identify an intracellular secretory protein and to dynamically track the spatiotemporal dynamics of a secretory protein secreted from a specific tissue in a living subject such that it can be effectively utilized for the research on endocrine signals between tissues, and particularly, since it can be applied in situ, the scope of application can be further expanded. Therefore, the present invention can be applied to various disease models or tissues to discover new biomarkers and therapeutic target proteins associated with diseases.Type: ApplicationFiled: February 28, 2022Publication date: September 22, 2022Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Hyun Woo Rhee, Issac Park, Jae Myoung Suh, Kwang Eun Kim
-
Patent number: 11440889Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: September 1, 2020Date of Patent: September 13, 2022Assignees: The Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Publication number: 20210147365Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: ApplicationFiled: September 1, 2020Publication date: May 20, 2021Applicants: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
-
Patent number: 10815203Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: September 10, 2019Date of Patent: October 27, 2020Assignees: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Publication number: 20200123113Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: ApplicationFiled: September 10, 2019Publication date: April 23, 2020Applicants: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
-
Publication number: 20190358296Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: ApplicationFiled: August 12, 2019Publication date: November 28, 2019Applicant: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Patent number: 10450277Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: November 27, 2018Date of Patent: October 22, 2019Assignees: The Salk Institute for Biological Studies, University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Patent number: 10398759Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: GrantFiled: September 13, 2017Date of Patent: September 3, 2019Assignee: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Publication number: 20190192630Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.Type: ApplicationFiled: March 7, 2019Publication date: June 27, 2019Applicant: Salk Institute for Biological StudiesInventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
-
Patent number: 10301268Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: GrantFiled: September 12, 2016Date of Patent: May 28, 2019Assignees: The Salk Institute for Biological Studies, University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F. W. Keana, Christopher Liddle
-
Patent number: 10293027Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: GrantFiled: February 26, 2018Date of Patent: May 21, 2019Assignee: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Publication number: 20190084939Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.Type: ApplicationFiled: November 27, 2018Publication date: March 21, 2019Applicants: Salk Institute for Biological Studies, The University of SydneyInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
-
Patent number: 10159711Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: GrantFiled: November 14, 2016Date of Patent: December 25, 2018Assignee: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Publication number: 20180200334Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: ApplicationFiled: February 26, 2018Publication date: July 19, 2018Applicant: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Publication number: 20180193418Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.Type: ApplicationFiled: March 2, 2018Publication date: July 12, 2018Applicant: Salk Institute for Biological StudiesInventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
-
Patent number: 9925241Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.Type: GrantFiled: October 21, 2014Date of Patent: March 27, 2018Assignee: Salk Institute for Biological StudiesInventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
-
Patent number: 9925243Abstract: The present disclosure provides chimeric proteins having an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor (FGF) 2 and the C-terminus comprises a portion of an FGF1 protein, wherein the chimeric protein comprises at least 95% sequence identity to SEQ ID NO: 9, 10, 11, 12 or 13. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.Type: GrantFiled: April 6, 2016Date of Patent: March 27, 2018Assignee: Salk Institute for Biological StudiesInventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Senyon Choe, Witek Kwiatkowski
-
Publication number: 20180036377Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: ApplicationFiled: September 13, 2017Publication date: February 8, 2018Applicant: Salk Institute for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Patent number: 9808508Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.Type: GrantFiled: August 18, 2016Date of Patent: November 7, 2017Assignee: Salk Institude for Biological StudiesInventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
-
Publication number: 20170291931Abstract: The present disclosure provides FGF2 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Thus, the disclosed mutant FGF2 proteins can be used to treat one or more metabolic diseases. In some examples, mutant FGF2 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels, for example to treat a metabolic disorder are also provided.Type: ApplicationFiled: June 8, 2017Publication date: October 12, 2017Applicant: Salk Institute for Biological StudiesInventors: Ronald M. Evans, Michael Downes, Annette Atkins, Jae Myoung Suh, Ruth T. Yu